<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559142</url>
  </required_header>
  <id_info>
    <org_study_id>IP CZD 2008-01-14</org_study_id>
    <nct_id>NCT01559142</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease</brief_title>
  <official_title>Efficacy and Safety of Induction Therapy With Three Doses of Infliximab in Patients With Crohn Disease Aged 7-17 Years-multicenter Open Study. Efficacy and Safety of Two Regimens of Maintenance Therapy in Patients With Crohn Disease Aged 7-17 Years-multicenter Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Memorial Health Institute, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Memorial Health Institute, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is confirmation of efficacy of induction therapy with three doses of&#xD;
      infliximab In patients with Crohn disease aged 7-17 years, and comparison of efficacy and&#xD;
      safety of two regiment of maintenance therapy:&#xD;
&#xD;
        1. Infliximab with immunomodulation&#xD;
&#xD;
        2. Infliximab alone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study project Screening (Days -14 do 0): Laboratory and endoscopic (up to three months before&#xD;
      Day 0) results will be obtained to check with inclusion/exclusion criteria.&#xD;
&#xD;
      Part A (Days 1 to 71): Induction therapy with 3 doses of infliximab 5 mg/kg will be applied&#xD;
      on days 1 - 15 - 43. Simultaneously in patients receiving steroids, steroid tapering will be&#xD;
      performed up to 71 Day. At Day 71 clinical (PCDAI) and endoscopic assessment will be done.&#xD;
      Patients with no clinical response will be qualified to Follow-up surveillance group.&#xD;
      Patients with clinical response present will be randomized to two groups of maintenance&#xD;
      therapy:&#xD;
&#xD;
      1. Infliximab with immunomodulation 2. Infliximab alone&#xD;
&#xD;
      Part B (Weeks 10 - 54): Patient with both groups will have scheduled visits at Weeks 14, 22,&#xD;
      30, 38, 46. Infliximab infusions and laboratory tests will be performed at each visit. At&#xD;
      Week 54 clinical (PCDAI) and endoscopic assessment will be done.&#xD;
&#xD;
      Follow Up: 4 weeks after last visit - SAE monitoring Aim of the study&#xD;
&#xD;
      The aim of the study is confirmation of efficacy of induction therapy with three doses of&#xD;
      infliximab In patients with Crohn disease aged 7-17 years, and comparison of efficacy and&#xD;
      safety of two regiment of maintenance therapy:&#xD;
&#xD;
        1. Infliximab with immunomodulation&#xD;
&#xD;
        2. Infliximab alone Drug dosing in therapy regimens.&#xD;
&#xD;
           Infliximab: 5 mg/kg mc In intravenous infusion lasting over 2 hrs. Azathioprine: 1,5 - 3&#xD;
           mg/kg/24h Methotrexate: 10 - 25 mg/week&#xD;
&#xD;
           Safety assessment&#xD;
&#xD;
           AE and SAE monitoring will be conducted during whole period of the study&#xD;
&#xD;
           Efficacy assessment&#xD;
&#xD;
           Primary endpoint&#xD;
&#xD;
           Part A:&#xD;
&#xD;
           • Clinical response defined as: Decrease of PCDAI ≥ 15 points AND PCDAI less than 30&#xD;
           points&#xD;
&#xD;
           • Remission defined as: PCDAI ≤ 10 points&#xD;
&#xD;
           Part B:&#xD;
&#xD;
             -  Loss of clinical response defined as:&#xD;
&#xD;
           Increase of PCDAI more than 15 points OR PCDAI &gt; 30 points&#xD;
&#xD;
           Secondary endpoints&#xD;
&#xD;
           Part A:&#xD;
&#xD;
           • Time to steroid cessation&#xD;
&#xD;
           Part B:&#xD;
&#xD;
           • Necessity to increase/change maintenance therapy with&#xD;
&#xD;
           o Surgery&#xD;
&#xD;
           o Increase of infliximab dose&#xD;
&#xD;
             -  Increase of immunomodulator dose&#xD;
&#xD;
             -  Steroids induction&#xD;
&#xD;
           Statistical methods&#xD;
&#xD;
             -  ITT analysis&#xD;
&#xD;
             -  Primary endpoints: chi2 tests, Kaplan-Meier analysis&#xD;
&#xD;
             -  Secondary endpoints: chi2 tests, Kaplan-Meier analysis, U Mann-Whitney analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical disease activity</measure>
    <time_frame>14 week and one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endoscopic disease activity</measure>
    <time_frame>14 week and one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>IFX TG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IFX alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab with azathioprine (IIFX + AZA)</intervention_name>
    <description>Infliximab with azathioprine during whole one year study</description>
    <arm_group_label>IFX TG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (IFX alone)</intervention_name>
    <description>Infliximab continuously; azathioprine stopped in 26 week</description>
    <arm_group_label>IFX alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with severe Crohn disease (PCDAI in anamnesis more than 51 points), with&#xD;
             PCDAI currently over 30 points, with no or loss of response for previous therapy&#xD;
             (except biological agents). Patients may have active fistulas.&#xD;
&#xD;
          2. Efficient methods of contraception in patients of childbearing potential during study&#xD;
             period and six months after.&#xD;
&#xD;
          3. Patients will be enrolled to Part B of the study whether they finish Part A with&#xD;
             clinical remission or clinical response.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to infliximab&#xD;
&#xD;
          2. Pregnancy and breastfeeding&#xD;
&#xD;
          3. Active tuberculosis or other severe infection: sepsis, opportunistic infections,&#xD;
             active CMV, yersinia pseudotuberculosis, pneumocystis carini, atypical mycobacteriosis&#xD;
&#xD;
          4. VZV infection, hepatitis, pneumonia during 3 months before Day 0 of the study&#xD;
&#xD;
          5. pancytopaenia and aplastic anemia&#xD;
&#xD;
          6. moderate and severe heart insufficiency (NYHA class III/IV), or unstable coronary&#xD;
             heart disease&#xD;
&#xD;
          7. chronic pulmonary insufficiency, chronic renal insufficiency, chronic liver&#xD;
             insufficiency&#xD;
&#xD;
          8. HIV infection&#xD;
&#xD;
          9. Presence of severe diseases of nervous system or severe endocrinological,&#xD;
             hematological, psychiatric diseases.&#xD;
&#xD;
         10. Demyelinisation syndrome or symptoms resembling Demyelinisation syndrome&#xD;
&#xD;
         11. Malignancy or premalignant conditions during 5 years before Day 0 of the study.&#xD;
&#xD;
         12. Severe infection currently present&#xD;
&#xD;
         13. Malignancy currently present&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaroslaw Kierkus, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Memorial Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, Hepatology and Feeding Disorders</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Memorial Health Institute, Poland</investigator_affiliation>
    <investigator_full_name>JAROSLAW KIERKUS</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Crohn Disease</keyword>
  <keyword>infliximab</keyword>
  <keyword>azathioprine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 26, 2015</submitted>
    <returned>September 24, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

